- Details
- Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations. Highlighting the journey from the inception of the trial to its execution, Hussain delves into the rigorous selection criteria and the strategic des...
|
- Details
- Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell's study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in treatm...
|
- Details
- Ruchika Talwar speaks with Chana Weinstock about the recent chemotherapy shortage affecting genitourinary cancers, notably muscle-invasive bladder cancer. Dr. Weinstock explains the complexity behind drug shortages, highlighting the manufacturing challenges of older, off-patent drugs like cisplatin and carboplatin. She discusses the FDA's limitations in mandating production increases and its strat...
|
- Details
- Alicia Morgans interviews Toni Choueiri about the results of the KEYNOTE-564 trial, marking a significant milestone in kidney cancer treatment with pembrolizumab showing an overall survival benefit as an adjuvant therapy. Dr. Choueiri highlights the trial's inclusion criteria, focusing on patients at some risk of recurrence post-surgery with clear cell RCC. The study, which involved 17 cycles of p...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressed on one novel hormonal therapy (NHT). This trial, which focuses on patients with extrapelvic soft tissue metastasis, has shown a significant reduction in the ri...
|
- Details
- Alicia Morgans and Cheryl Lee discuss the need for equitable representation in clinical trials. Dr. Lee emphasizes the underrepresentation of minorities, low-income individuals, and those in rural areas. She highlights strategies for improvement, such as revising eligibility criteria, reducing the burden of trial participation, and employing patient navigators. Dr. Lee also mentions the importance...
|
- Details
- Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...
|
- Details
- Sam Washington and Isla Garraway discuss the Prostate Cancer Foundation's new screening guidelines for prostate cancer in Black men. Dr. Garraway highlights the guidelines' development process, involving a diverse panel from various disciplines, including patient advocates, to address the unique risks Black men face regarding prostate cancer. These guidelines aim to inform Black men about their in...
|
- Details
- Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation pr...
|
- Details
- Zach Klaassen engages Andrew Laccetti in a discussion about Masofaniten (EPI-7386), a pioneering anti-androgen therapy targeting the N-terminal domain of the androgen receptor, aimed at overcoming resistance mechanisms observed with current prostate cancer treatments. Detailing the progression from preclinical data to clinical trials, Dr. Laccetti highlights Masofaniten's potential synergy with en...
|
